IPSC vs RARE · rev $109.2M vs rev $350.0M
Century Therapeutics Inc (IPSC) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
Century Therapeutics Inc (IPSC) is a biotechnology company listed on US.
Ultragenyx (RARE) is a biotechnology company listed on US.
Latest reported IPSC revenue for 2025-09-30 was $109.2M. Net income was $9.6M. Revenue was up 0.0% from 2025-06-30 to 2025-09-30. IPSC currently screens at market cap $47.8M.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
IPSC currently screens at market cap $47.8M. RARE currently screens at market cap $2.79B.
Not investment advice. Open the IPSC and RARE stock pages for the full models.
Not investment advice.